UPDATE: Lynx Therapeutics Fires 30 Percent of Staff | GenomeWeb

NEW YORK, April 18 - Lynx Therapeutics today said it has cut approximately 30 percent of its domestic workforce, or 60 people, and said it expects to focus more on its MPSS gene-expression technology and on the development of its Protein ProFiler proteomics technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.